uBriGene Biosciences Inc.

is a leading player in the biotechnology industry, providing a comprehensive suite of services for cell and gene therapy. Established in 2015 and headquartered in Canada, uBriGene has positioned itself as a pioneering CDMO service provider, offering GMP-grade plasmid and T cell production services for large-scale CAR-T productions. The company boasts of two state-of-the-art GMP facilities with over 133,000 sq ft of clean suites and a commendable track record, having produced 65 batches of GMP plasmids as of 2021. Their integrated innovative CGT CDMO platforms cater to the demands of the cell and gene therapy industry, with a focus on accelerating development from target to market. uBriGene's offerings include viral vectors such as adenovirus and lentivirus vectors, alongside a versatile selection of research-grade, GMP-ready, or GMP-grade plasmids. Their fermentation capacity ranges from 5L to 500L, and their two-step purification technology enables a fast and cost-effective cell harvesting process. In a significant development, uBriGene secured a notable CNY150.00M Series C investment on 19 April 2023, attracting backing from FOF Capital, Jinan Industrial Development Group, and Guotai Junan Innovation Investment. This investment underscores the confidence that notable industry players have in uBriGene's capabilities and the potential for growth in the evolving field of cell and gene therapy.